Eisai expands marketing presence in Austria
This article was originally published in Scrip
Eisai has set up a new sales and marketing subsidiary in Austria. Capitalised at €35,000, the Vienna-based operation is wholly owned by the Japanese firm's Eisai Europe subsidiary in London. Eisai began sales in Austria in 2005 through its German operation, and already markets a number of products there. The new Austrian operation will also continue to support business operations in Central and Eastern Europe, where Eisai said it might expand in the future. The company now has 10 subsidiaries across Europe.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.